Researchers Find That Vacc-4x Therapeutic Peptide-Based HIV Vaccine Increases CD4 T-Cells in Chronically Infected HIV-1 Patients on Antiretroviral Therapy (ART)
October 21, 2009 08:00 ET
|
Bionor Immuno
PARIS--(Marketwire - October 21, 2009) - EMBARGOED FOR RELEASE UNTIL 2:00pm CEST, or 8:00am
USA EST -- Abstract #173886 -- An immunological analysis of a Phase II
clinical trial demonstrated that the...
Bionor Immuno Welcomes Renowned Virologist Robert Redfield, MD to Its Clinical Advisory Board
October 19, 2009 10:00 ET
|
Bionor Immuno
BETHESDA, MD and OSLO, NORWAY and PARIS--(Marketwire - October 19, 2009) - Bionor Immuno
announced today at the AIDS Vaccine 2009 conference in Paris, France, that
Robert Redfield, MD, Associate...
HemoBioTech Gains Congressional Recognition of Its Blood Substitute Technology
August 17, 2009 08:38 ET
|
HemoBiotech
DALLAS, TX--(Marketwire - August 17, 2009) - HemoBioTech, Inc. (OTCBB: HMBT) has been working
with a coalition of small biotechnology firms to implement legislation that
will strengthen the Federal...
Gede Foundation Trains HIV/AIDS Counseling and Testing Workers in Nigeria
May 15, 2009 16:49 ET
|
Gede Foundation
WASHINGTON, DC--(Marketwire - May 15, 2009) - Gede Foundation, in collaboration
with the Society for Family Health and the Nursing & Midwifery Council of
Nigeria, trained healthcare workers on...
Norwegian Research Council Names Bionor Immuno "Most Innovative Company of the Year"
December 05, 2008 08:00 ET
|
Bionor Immuno
OSLO, NORWAY and BETHESDA, MD--(Marketwire - December 5, 2008) - Bionor Immuno officials today
accepted the Norwegian Research Council's prestigious "Most Innovative
Company of the Year" award. The...
Samaritan to Highlight Oral HIV Entry Inhibitor and Novel Alzheimer's Drug At BioPartnering Europe to Seek Partnering Opportunities
October 03, 2006 09:30 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, Oct. 3, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today, it will highlight the uniqueness and advantages of its oral HIV...
Viral Genetics, Inc. Provides Update on Phase 3 Trial of VGV-1 in South Africa
July 21, 2005 10:00 ET
|
Viral Genetics, Inc.
AZUSA, Calif., July 21, 2005 (PRIMEZONE) -- Viral Genetics, Inc. (OTCBB:VRAL), a drug development company developing a biologic therapy for HIV infection, today announced that the eight-week,...